# EPCORE DLBCL-1 (NCT04628494)

> A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

No report yet. It can be ordered.

- Drugs tested: epcoritamab
- Indication: relapsed/refractory diffuse large B-cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04628494
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genmab
- Conditions: Diffuse Large B-cell Lymphoma
- Interventions: Epcoritamab; Investigator's Choice Chemotherapy
- Enrollment: 483
- Primary outcome: Overall Survival (OS)

## Indexed commentary on EPCORE DLBCL-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- YouTube: 1
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=epcore-dlbcl-1-nct04628494

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04628494", "email": "<work email>"}; the inbox owner confirms by the emailed link.